Corcept Therapeutics (CORT) Total Non-Current Liabilities (2017 - 2026)

Corcept Therapeutics (CORT) has 10 years of Total Non-Current Liabilities data on file, last reported at $161.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 8.49% year-over-year to $161.6 million; the trailing twelve-month figure through Mar 2026 stood at $161.6 million (up 8.49% YoY), and the FY2025 full-year result was $173.7 million, up 18.24% from the prior year.
• Total Non-Current Liabilities slipped to $161.6 million in Q1 2026, from $173.7 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $177.6 million in Q3 2025 to a low of $49.1 million in Q2 2022.
• A 5-year average of $113.3 million and a median of $106.4 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities rose 8.05% in 2022 and jumped 129.65% in 2023, its largest moves.
• Tracing CORT's Total Non-Current Liabilities over 5 years: stood at $72.5 million in 2022, then surged by 44.16% to $104.5 million in 2023, then soared by 40.55% to $146.9 million in 2024, then climbed by 18.24% to $173.7 million in 2025, then dropped by 6.97% to $161.6 million in 2026.
• Business Quant data shows CORT's Total Non-Current Liabilities at $161.6 million in Q1 2026, $173.7 million in Q4 2025, and $177.6 million in Q3 2025.